Ateev Mehrotra, M.D., and Lori Uscher-Pines, Ph.D.
doi : 10.1056/NEJMp2210790
Vol. 387 No. 20
Helen K. Hughes, M.D., M.P.H., Brian W. Hasselfeld, M.D., and Jeremy A. Greene, M.D., Ph.D.
doi : 10.1056/NEJMp2118292
Matthew R. Golden, M.D., M.P.H., and Judith N. Wasserheit, M.D., M.P.H.
doi : 10.1056/NEJMp2212262
Lukoye Atwoli, Gregory E. Erhabor, Aiah A. Gbakima, Abraham Haileamlak, Jean-Marie Kayembe Ntumba, James Kigera, Laurie Laybourn-Langton, Bob Mash, Joy Muhia, Fhumulani Mavis Mulaudzi, David Ofori-Adjei, Friday Okonofua,
doi : 10.1056/NEJMp2213503
Oscar F. Lovelace, Jr., M.D., Debra Malina, Ph.D., and Mark A. Pacult, M.D.
doi : 10.1056/NEJMp2213554
Kassoum Kayentao, M.D., Ph.D., M.P.H., Aissata Ongoiba, M.D., M.P.H., Anne C. Preston, R.N., Sara A. Healy, M.D., M.P.H., Safiatou Doumbo, M.D., Ph.D., Didier Doumtabe, Pharm.D., Abdrahamane Traore, M.D., Hamadi Traore, M.D., Adama Djiguiba, M.D., Shanping Li, M.S., Mary E. Peterson, B.S., Shinyi Telscher, Pharm.D.,
doi : 10.1056/NEJMoa2206966
CIS43LS is a monoclonal antibody that was shown to protect against controlled Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody can prevent P. falciparum infection in a region in which the infection is endemic is unknown.
Arnaud W. Thille, M.D., Ph.D., Arnaud Gacouin, M.D., Rémi Coudroy, M.D., Ph.D., Stephan Ehrmann, M.D., Ph.D., Jean-Pierre Quenot, M.D., Ph.D., Mai-Anh Nay, M.D., Christophe Guitton, M.D., Damien Contou, M.D., Guylaine Labro, M.D., Jean Reignier, M.D., Ph.D., Gael Pradel, M.D., Gaëtan Beduneau, M.D.,
doi : 10.1056/NEJMoa2209041
Spontaneous-breathing trials can be performed with the use of either pressure-support ventilation (PSV) or a T-piece. Whether PSV trials may result in a shorter time to tracheal extubation than T-piece trials, without resulting in a higher risk of reintubation, among patients who have a high risk of extubation failure is unknown.
Michelle L. O’Donoghue, M.D., M.P.H., Robert S. Rosenson, M.D., Baris Gencer, M.D., M.P.H., J. Antonio G. López, M.D., Norman E. Lepor, M.D., Seth J. Baum, M.D., Elmer Stout, M.D., Daniel Gaudet, M.D., Ph.D., Beat Knusel, Ph.D., Julia F. Kuder, M.A., Xinhui Ran, M.S., Sabina A. Murphy, M.P.H.,
doi : 10.1056/NEJMoa2211023
Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver.
Hiam Chemaitelly, Ph.D., Sawsan AlMukdad, M.Sc., Houssein H. Ayoub, Ph.D., Heba N. Altarawneh, M.D., Peter Coyle, M.D., Patrick Tang, M.D., Ph.D., Hadi M. Yassine, Ph.D., Hebah A. Al-Khatib, Ph.D., Maria K. Smatti, M.Sc., Mohammad R. Hasan, Ph.D., Zaina Al-Kanaani, Ph.D., Einas Al-Kuwari, M.D.,
doi : 10.1056/NEJMoa2210058
The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses.
Kawtar Bouirig, M.D., and Ouafae Cherkaoui, M.D., Ph.D.
doi : 10.1056/NEJMicm2205233
Jennifer S. Temel, M.D., David M. Dudzinski, M.D., Subba R. Digumarthy, M.D., Colleen M. Keyes, M.D., Florence K. Keane, M.D., and Daniel Shepherd, M.D., Ph.D.
doi : 10.1056/NEJMcpc2211354
Umberto D’Alessandro, M.D., Ph.D.
doi : 10.1056/NEJMe2213148
C. Corey Hardin, M.D., Ph.D.
doi : 10.1056/NEJMe2212594
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Peter Marks, M.D., Ph.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2214911
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟